Pharmaceutical composition

Details Pharmaceutical composition Pharmaceutical composition

1995-06-07

1997-12-09

Sayala, Chhaya D.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 21, 530350, A61K 3514

Patent

active

056960905

ABSTRACT:
Polypeptide pharmaceutical compositions having improved stability and resistance to aggregation, particle formation and precipitation comprising a polypeptide pharmaceutical and poloxamer surfactants alone, or in combination with polysorbate surfactants. Preferred polypeptides stabilized are bactericidal/permeability increasing (BPI) protein, biologically active fragments of BPI, biologically active analogs of BPI, and biologically active variants of BPI.

REFERENCES:
patent: 3839314 (1974-10-01), Fekete et al.
patent: 4478829 (1984-10-01), Landaburu et al.
patent: 4719239 (1988-01-01), Muller et al.
patent: 4933179 (1990-06-01), Allison et al.
patent: 4997664 (1991-03-01), Williams
patent: 5030448 (1991-07-01), Hunter
patent: 5037664 (1991-08-01), Shaked et al.
patent: 5039520 (1991-08-01), Hunter
patent: 5041288 (1991-08-01), Hunter
patent: 5071649 (1991-12-01), Hunter
patent: 5089274 (1992-02-01), Marra et al.
patent: 5096885 (1992-03-01), Pearlman et al.
patent: 5118528 (1992-06-01), Fessi et al.
patent: 5118794 (1992-06-01), Grangeorge et al.
patent: 5133908 (1992-07-01), Stainmesse et al.
patent: 5152979 (1992-10-01), Hunter
patent: 5171739 (1992-12-01), Scott
patent: 5182106 (1993-01-01), Mezrow et al.
patent: 5198541 (1993-03-01), Elsbach et al.
patent: 5234683 (1993-08-01), Hunter et al.
patent: 5234908 (1993-08-01), Szabo et al.
patent: 5234912 (1993-08-01), Marra et al.
patent: 5308834 (1994-05-01), Scott et al.
patent: 5334584 (1994-08-01), Scott et al.
patent: 5348942 (1994-09-01), Little, II et al.
patent: 5439807 (1995-08-01), Grinna
patent: 5488034 (1996-01-01), McGregor et al.
FDA, Division of Drug Information Resources, "Inactive Ingredient Guide including list of Currently Marketed Injectable Products," (1991).
FDA review and basis for approval of OB-NDA-86-0909 on Fluosol.RTM. (20% Intravascular Perflorochemical Emulsion), The Green Cross Corp. (1989).
Gazzano-Santoro, et al., "High-Affinity Binding of the Bactericidal/Permeability-Increasing Protein and a Recombinant Amino-Terminal Fragment to the Lipid A Region Lipopolysaccharide," Infection and Immunity, vol. 60, 4754-4761, (Nov. 1992).
Genentech, Inc., "A Tissue Plasminogen Activator," Product Information (1987).
Gray, et al., "Cloning of the cDNA of a Human Neutrophil Bactericidal Protein," The Journal of Biological Chemistry, vol. 264, No. 16, 9505-9509 (Jun. 5, 1989).
The Green Cross Corporation, "Peruflorochemical Blood Substitutes," Technical Info. Series Nos. 5 & 7 (1978 and 1981).
Henson, et al., "The Surface Coagulation of Proteins During Shaking," J. Colloid & Interface Sci., 32(1):162-165 (Jan. 1970).
ICI Americas, Inc., "ICI Americas Products For Cosmetics and Pharmaceuticals," Chapters 1-4, pp. 1-39 (1977).
ICI Americas, Inc., "The HLB System," Chapters 1-8, pp. 3-20 (1984).
Kaplan and Fraser, "Formation of Fibres from Protein Monolayers," Nature, 171(4352):559-560 (Mar. 28, 1953).
Krantz, et al., "Sugar Alcohols," Bulletin of School of Medicine, U. of ME, 36:48-56 (1951).
Levine, et al., "The Use of Surface Tension Measurements in the Design of Antibody-Based Product Formulations," J. Parenteral Sci. & Tech., 45(3):160-165 (May-Jun. 1991).
MacRitchie, "Proteins at Interfaces," Adv. Protein Chem., 32:283-326 (1978).
Neugebauer, "A Guide to the Properties and Uses of Detergents in Biology and Biochemistry," Calbiochem.RTM. Brand Chemicals, Hoechst Celanese Corp. (1987).
Ooi, et al., "Endotoxin-neutralizing Properties of the 25 kD N-Terminal Fragment and a Newly Isolated 30 kD C-Terminal Fragment of the 55-60 kD Bactericidal/Permeability-increasing Protein of Human Neutrophils," J. Exp. Med., vol. 174, 649-655 (Sep., 1991).
Ortho Pharmaceutical Corporation, "Orthocolone OKT-3," Product Information Package Insert (1986).
The U.s. Pharmacopeia USPXXII, pp. 1763, 1857, and NFXVII,pp. 1960-1961, 1967-1968.
Wang, et al., "Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers," J. Parenteral Sci. Tech., 42(Supp. 25):S4-526 (1988).
Weiss, et al., "Cellular and Subcellular Localization of the Bactericidal/Permeability-Increasing Protein of Neutrophils," Blood, vol. 69, No. 2, 652-659 (Feb., 1987).
Weiss, et al., "Resistance to Gram-negative Bacteria to Purified Bactericidal Leukocyte Proteins", J. Clin. Invest., 65:619-628 (Mar., 1980).
Wyandotte Chemicals Corporation, "Information on Applications of Pluronics," pp. 1-13 (Mar. 1, 1952).
Little et al., "Functional Domains of Recombinant Bactericidal/Permeability Increasing Protein (rBPI.sub.23)", J. Biol. Chem., 269(3):1865-1872 (Jan. 21, 1994).

Affiliated with

Also associated with

Rating

Pharmaceutical composition does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1607727